Plus Therapeutics, Inc. (PSTV)
NASDAQ: PSTV · Real-Time Price · USD
5.95
-0.04 (-0.67%)
At close: Apr 28, 2026, 4:00 PM EDT
5.91
-0.04 (-0.67%)
After-hours: Apr 28, 2026, 6:31 PM EDT

Plus Therapeutics Stock Forecast

PSTV's stock price has decreased by -70.4% in the past year and price targets may not have had time to catch up.

Stock Price Forecast

The 3 analysts with 12-month price forecasts for Plus Therapeutics stock have an average target of 55, with a low estimate of 25 and a high estimate of 75. The average target predicts an increase of 824.37% from the current stock price of 5.95.

Analyst Consensus: Strong Buy
Target Low Average Median High
Price $25 $55 $65 $75
Change +320.17% +824.37% +992.44% +1160.5%

Analyst Ratings

The average analyst rating for Plus Therapeutics stock from 4 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.

Recommendation Trends

Rating Nov '25Dec '25Jan '26Feb '26Mar '26Apr '26
Strong Buy 444433
Buy 000000
Hold 000011
Sell 000000
Strong Sell 000000
Total 444444

Latest Forecasts

Analyst Firm Rating Rating Action Price Target Upside Date
Ascendiant Capital
Ascendiant Capital
Strong Buy
Maintains
$475$65
Strong Buy Maintains $475$65 +992.44% Apr 9, 2026
D. Boral Capital
D. Boral Capital
Hold
Downgrades
n/a
Hold Downgrades n/a n/a Mar 31, 2026
D. Boral Capital
D. Boral Capital
Strong Buy
Maintains
$75
Strong Buy Maintains $75 +1,160.50% Mar 19, 2026
HC Wainwright & Co.
HC Wainwright & Co.
Strong Buy
Maintains
$50$25
Strong Buy Maintains $50$25 +320.17% Jan 23, 2026
D. Boral Capital
D. Boral Capital
Strong Buy
Maintains
$125$100
Strong Buy Maintains $125$100 +1,580.67% Jan 22, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
5.90M
from 5.21M
Increased by 13.20%
Revenue Next Year
21.33M
from 5.90M
Increased by 261.48%
EPS This Year
-3.70
from -7.25
EPS Next Year
-2.17
from -3.70
Fiscal Year FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 FY 2026 FY 2027
Period Ending Dec 31, 2021 Dec 31, 2022 Dec 31, 2023 Dec 31, 2024 Dec 31, 2025 Dec 31, 2026 Dec 31, 2027
Revenue
-224.00K4.91M5.82M5.21M5.90M21.33M
Revenue Growth
--2,093.30%18.54%-10.49%13.20%261.48%
EPS
-416.25-289.58-106.00-58.52-7.25-3.70-2.17
EPS Growth
-------
Forward PE
-------
No. Analysts -----76
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.

Revenue Forecast

Revenue 20262027202820292030203120322033
High 11.9M 29.4M
Avg 5.9M 21.3M
Low 3.9M 9.8M

Revenue Growth

Revenue Growth 20262027202820292030203120322033
High
127.6%
398.2%
Avg
13.2%
261.5%
Low
-24.8%
66.1%

EPS Forecast

EPS 202620272028202920302031
High -2.89 -1.84
Avg -3.70 -2.17
Low -4.66 -2.45

EPS Growth

EPS Growth 202620272028202920302031
High - -
Avg - -
Low - -
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.